BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > IT > article

Genexine works with domestic company to develop antibody treatment

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : July 20, 2020, 14:53 | Updated : July 20, 2020, 14:53
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Genexine]


SEOUL -- Genexine, a clinical-stage biotechnology company, will cooperate with a domestic biotech company in developing an antibody that can neutralize the virus of COVID-19. Genexine has already been involved in a state-commissioned research consortium to develop a DNA vaccine material for COVID-19.

Y-Biologics, known for its expertise in antibody science, has discovered an antibody candidate. Genexine and Y-Biologics will jointly pay for the development of antibody treatments and share intellectual property rights. Genexine is responsible for the commercialization of products and technologies

South Korea has unveiled a roadmap for the treatment of COVID-19 to develop plasma treatment by the year's end as well as antibody treatment and vaccines next year. GC Pharma, a biotech company, has started producing products for clinical trials of GC5131A, an immunoglobulin drug based on plasma containing antibodies.

GC Pharma is working with the state-run National Institutes of Health to develop plasma treatment. As of July 20, 1,032 people have expressed their intention to donate plasma and GC Pharma has collected blood from 642 of them..

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .  Daewoong allowed to conduct Foistars clinical testing as COVID-19 treatment .
    Daewoong allowed to conduct Foistar's clinical testing as …
  • .Researchers detect antibodies 8 months after COVID-19 infection in asymptomatic or mildly symptomatic persons.
    Researchers detect antibodies 8 months after COVID-19 infect…
  • .Anti-epidemic center warns of silent community infection by young untraceable virus carriers.
    Anti-epidemic center warns of silent community infection by …
  • .GC Labcell exports original technology for U.S. deal to develop cell therapies.
    GC Labcell exports original technology for U.S. deal to deve…
  • .S. Korea earns $2.27 billion with exports of in-vitro diagnostic devices.
    S. Korea earns $2.27 billion with exports of in-vitro diagno…

Real Time Photo News

  • .Girl band (G)I-DLE shrinks size to five members after school bullying controversy.

    Girl band (G)I-DLE shrinks size to five members after school bullying controversy

  • .Singer-actress IU reveals release schedule for album LILAC.

    Singer-actress IU reveals release schedule for album 'LILAC'

  • .S. Korea to build state-run K-pop concert hall for unaffordable online performances .

    S. Korea to build state-run K-pop concert hall for unaffordable online performances

  • .BLACKPINK member Rosé to release solo album in March.

    BLACKPINK member Rosé to release solo album in March

  • .BTS agency posts record earnings in 2020 on brisk online activities and album sales .

    BTS agency posts record earnings in 2020 on brisk online activities and album sales

Latest News

more+

  • Young woman faces trial for eating hamberger and insulting train passenger
  • Girl band (G)I-DLE shrinks size to five members after school bullying controversy
  • S. Korean companies to build combined cycle power plant in Thailand
  • Transparent LED film displays videos and images at official venue of Busan film festival
  • Daredevil surfers to be fined for ignoring storm warning
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view